20 Million

US adults are treated annually for acute muscle spasms

Sustained involuntary contractions of a muscle or muscle group that cannot relax
Debilitating medical condition usually localized within the spinal structure
Current products do not meet patient needs
41%
46%
52%
Cause Drowsiness
Impact on
Cognitive Function
Patient Dislike of
Sedative Impact

Barriers of Current Treatment Options for Acute Muscle Spasm of the Back

Barriers of Current Treatment Options for Acute Muscle Spasm of the Back

52%
46%
41%
Cause Drowsiness
Impact on
Cognitive Function
Patient Dislike of
Sedative Impact

Compare the Target Adverse Event Profile of OMZYA® to Other Approved Muscle Relaxants

Cyclobenzaprine

Flexeril®

Drowsiness

Dry mouth, fatigue, headache

PATIENT INFORMATION​
​May impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving an motor vehicle
search

Metaxalone

Skelaxin®

Drowsiness

Dizziness, headache, nervousness or “irritability”​

​Digestive: nausea, vomiting, gastrointestinal upset

Immune System: hypersensitivity reaction, rash with or without pruritus

​ Hematologic: leukopenia; hemolytic anemia

Hepatobiliary: jaundice

PATIENT INFORMATION​
​May impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving an motor vehicle
search

Carisoprodol

Soma®

Drowsiness

Dizziness, headache,

WARNINGS & PRECAUTIONS
Due to sedative properties,
may impair ability to perform hazardous tasks such as driving or operating machinery
search

Drowsiness

The ONLY
potential,
non-opioid,
non-drowsy,
non-CNS impairing
muscle relaxant

Based on completed Phase 1 and Phase 2 studies of OMZYA®

“I would use a product like OMZYA® a lot more than other muscle relaxants because of the side effect profile: this would be first line instead of Flexeril … I think over time such a product could replace Flexeril as patients wouldn’t be so sleepy.”

Primary Care Provider

Neurana conducted qualitative and quantitative prescriber research survey of an aggregate of over 245 prescribers that commonly treat muscle spasms
Privacy Policy Terms of Use